Selecting Targeted Therapies for Patients with Renal Cell Carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 9, 2011, Pages 997-1007

  Plimack, Elizabeth R ^a   Hudes, Gary R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Carcinoma; Clear cell renal cell carcinoma; Genetics; Kidney neoplasms; Non clear cell renal cell carcinoma; Pathology; Renal cell; Therapy

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; AMG 836; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; DOVITINIB; DOXORUBICIN; ENTINOSTAT; ERLOTINIB; EVEROLIMUS; FORETINIB; GEMCITABINE; INTERLEUKIN 2; ISPINESIB; MDX 1105; MDX 1106; PANOBINOSTAT; PAZOPANIB; PERIFOSINE; RAMUCIRUMAB; RILOTUMUMAB; RX 0201; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; WARFARIN;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COLON CANCER; CYTOPENIA; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG CONGESTION; METASTASIS; MULTICENTER STUDY (TOPIC); NEPHRECTOMY; NEUROLOGIC DISEASE; NEUTROPENIA; PAPILLARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80052974211     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0084     Document Type: Review

References (67)

1. Motzer RJ, Agarwal N, Beard C, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2, 2011. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf. Accessed July 20, 2011.
2. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502-1507.
3. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184:859-864.
4. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076-4081.
5. Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010;106:1270-1276.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659. (Pubitemid 33126820)
7. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-970. (Pubitemid 32913522)
8. Escudier B. Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol 2011;22:995-996.
9. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540. (Pubitemid 29368255)
10. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296. (Pubitemid 34032623)
11. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-763.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
13. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-2575. (Pubitemid 37509519)
14. McDermott DF, Ghebremichael MS, Signoretti S, et al. The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4514.
15. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32:181-185.
16. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5025.
17. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial [abstract]. J Clin Oncol 2011;29(Suppl 7):Abstract LBA308.
18. Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int, in press.
19. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
20. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-480.
21. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
22. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
23. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470-1476.
24. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-17.
25. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-4541. (Pubitemid 350035309)
26. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434. (Pubitemid 36910021)
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
28. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
29. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524. (Pubitemid 43854967)
30. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.
31. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-4468.
32. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5032.
33. Sweeney P, El-Naggar AK, Lin SH, et al. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002;168:51-55. (Pubitemid 34640783)
34. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs, in press.
35. Plimack ER, Jonasch E, Bekele BN, et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study [abstract]. Presented at the 2010 Genitourinary Cancer Symposium; March 5-7, 2010; San Francisco, California. Abstract 4604.
36. Ravaud A, Oudard S, Gravis-Mescam G, et al. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 5146.
37. Dutcher JP, De Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-209.
38. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:5788-5793.
39. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551. (Pubitemid 39318900)
40. Haas N, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol, in press.
41. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol, in press.
42. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009;27:235-241.
43. Molina AM, Tickoo SK, Ishill N, et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol, in press.
44. Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002;94:111-116. (Pubitemid 34049048)
45. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007;177:1698-1702. (Pubitemid 46560664)
46. Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology 2007;70:878-882. (Pubitemid 350192580)
47. Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP. Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol 2003;26:489-492. (Pubitemid 37248268)
48. Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology 2008;72:659-663.
49. Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer 2010;55:1217-1220.
50. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127-131.
51. Larkin JM, Fisher RA, Pickering LM, et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011;29:e241-242.
52. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115:2368-2375.
53. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439.
54. Molina AM, Feldman DR, Ginsberg MS, et al. Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2011;29(Suppl 7):Abstract 311.
55. Patel PH, Senico PL, Curiel RE, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7:24-27.
56. Escudier BJ, Negrier S, Gravis G, et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial [abstract]. J Clin Oncol 2010;28:Abstract 4516.
57. Sadeghi S, Albiges L, Wood LS, et al. Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): feasibility and clinical outcome [abstract]. J Clin Oncol 2011;29(Suppl 7):Abstract 307.
58. Hudes GR, Carducci MA, Choueiri TK, et al. NCCN Task Force Report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Cancer Netw 2011;9:S1-29.
59. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-984. (Pubitemid 47629888)
60. Sonpavde G, Hutson TE. Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. Clin Genitourin Cancer 2008;6(Suppl 1):S29-36.
61. Bhargava P, Esteves B, Al-Adhami M, et al. Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2011;29(Suppl 7):Abstract 327.
62. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
63. Merchan JR, Pitot HC, Qin R, et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 5039.
64. Hainsworth JD, Spigel DR, Burris HA III. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28:2131-2136.
65. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5011.
66. Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3512.
67. Cen P, Daleiden A, Doshi G, et al. A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract e16056.